🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficiency of Asiaticoside as Intracanal Medication in Revascularization Process

RecruitingNAAges 8 Years - 18 YearsAllMansoura University
NCT07802340 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study assess the ability of Asiaticoside based Intracanal medication compared to the commonly used Intracanal medicament ( calcium hydroxide Ca(OH) 2) on the outcome of the revascularization process in immature permanent teeth with pulp necrosis

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Both gender * patients having permanent anterior teeth with necrotic pulp and immature apex * Good general health * pulp space not needed for post and core Exclusion Criteria: * Radiographic identification of root fracture or abnormality * Uncooperative patients * Root resorption (internal or external)
💊

What it tests

  • Intracanal medication
📍

Where

1 site
Mansoura University
Al Mansurah, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy